Ultragenyx (RARE) stock plunged 45% after apazunersen missed Phase 3 trial endpoints for Angelman syndrome, raising concerns about future programs. The post Ultragenyx (RARE) Shares Plunge 45% Following Critical Drug Trial Failure appeared first on Blockonomi.
Ultragenyx (RARE) Shares Plunge 45% Following Critical Drug Trial Failure
其他语言标题
- EnglishUltragenyx (RARE) shares plunge 45% following critical drug trial failure
- 한국어Ultragenyx (RARE) 주가, 핵심 약물 임상시험 실패로 45% 급락